Ensoma develops one-time, off-the-shelf, in vivo treatments that utilize advanced hematopoietic stem cell engineering to precisely modify cells within the hematopoietic system. This technology aims to provide durable cures for genetic, immune, and oncological diseases by addressing the limitations of traditional therapies that often require multiple treatments.
Funding
$205M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for genetic, immune, and oncological diseases often require multiple administrations and do not always provide durable cures. Traditional therapies can be limited in their ability to precisely modify cells within the hematopoietic system, leading to potential side effects and incomplete disease remission.
Solution
Ensoma is developing one-time, off-the-shelf, *in vivo* treatments that precisely and durably engineer hematopoietic stem cells (HSCs) to cure diseases from within. Their platform combines an *in vivo* delivery system with a gene engineering toolkit to selectively modify cells of the entire hematopoietic system. This approach aims to provide a simpler, faster, and safer patient experience compared to traditional therapies. By engineering HSCs *in vivo*, Ensoma seeks to overcome the limitations of existing treatments and offer durable cures for a range of diseases.
Target Audience
The primary target audience includes patients suffering from genetic, immune, and oncological diseases, as well as healthcare providers seeking more effective and durable treatment options.
Features
- *In vivo* hematopoietic stem cell (HSC) engineering technology
- Off-the-shelf delivery system for simplified administration
- Advanced gene engineering toolkit for precise cell modification
- Ability to selectively and durably modify any cells of the hematopoietic system
- One-time therapy approach for long-lasting effects